EMA approves marketing authorization application for Lumoxiti®
Category: #health  By Mateen Dalal  Date: 2020-01-03
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

EMA approves marketing authorization application for Lumoxiti®

Innate Pharma SA, a commercial-stage oncology-focused biotech firm, has successfully attain Marketing Authorization Application (MMA) approval for Lumoxiti from the European Medicines Agency (EMA). For the record, Lumoxiti is a first-in-class drug directed for adult patients who are suffering from refractory or relapsed hairy cell leukemia (HCL) and have received a minimum two preceding systemic therapies, including treatment with a purine nucleoside analog. 

Speaking on the approval, Pierre Dodion, MD, Executive VP & CMO, Innate Pharma, said that the drug, following its authorization by the EMA, would become first treatment available in Europe for relapsed or refractory HCL patients in over twenty years, potentially transforming the standard of care for these patients.

Dodion assured that their firm is dedicated towards addressing the unmet need for treating this rare type of cancer that could result in fatal conditions and would bring this drug to patent in Europe as soon as possible.

As per reports, the EMA filing was based on the final study of the Phase III trial of Lumoxiti, demonstrated at ASH 2019. According to the data, around 36 percent (29/80) of the relapsed or refractory HCL patients attained durable complete response (specified as a CR) with a hematological remission retained for at least 180 days.

The ORR (objective response rate) was at 75%, whereas 81% of patients with CR underwent elimination of minimal residual disease as reflected by MRD-negative status. Additionally, there was a 61% possibility that patients who attained a CR would retain it after five years.

Reportedly, the EMA filing acceptance for Lumoxiti follows the U.S. FDA (Food and Drug Administration) approval in Sept. 2018.

About Innate Pharma S.A.

It is an oncology-focused biotech organization dedicated to improving clinical and treatment results for patients through therapeutic antibodies that utilize the immune system to fight against cancer.
 

Souce Creidit – https://www.innate-pharma.com/en/news-events/press-releases/european-medicines-agency-accepts-regulatory-submission-lumoxiti-relapsed-or-refractory-hairy-cell-leukemia

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

By Mateen Dalal

GM will recover almost all the costs from the recall of its Bolt EV models. Despite the EV battery manufacturing mishap from LG, the two companies will continue to work together. General Motors (GM) has agreed to recover around USD 1.9 billion f...

Tata Motors records 25% jump in global sales in second quarter of 2021

Tata Motors records 25% jump in global sales in second quarter of 2021

By Mateen Dalal

The automaker’s annual wholesale growth has been around 24%. The company saw a 10% rise in passenger car sales during Q2 2021, as compared to the same period in 2020. Tata Motors Limited reported substantial growth in Q2 2021, with its glo...

Carbon Budgets for corporate business travels to hit airlines: Report

Carbon Budgets for corporate business travels to hit airlines: Report

By Mateen Dalal

With major companies considering ways to reduce carbon emissions from corporate travel, airlines are preparing for a setback in business-class travel, which is an important revenue driver according to industry experts and executives. The airline ind...